Drug intelligence / Profile preview

LXH-2103

Development stage: Unknown
Lead developer: Shandong Xinhua Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

LXH-2103 is a small molecule analgesic developed by Shandong Xinhua Pharmaceutical. It is classified as a Class 1 new chemical entity (NCE) in China, specifically designed for the management of moderate to severe postoperative pain. The drug acts as an agonist of the mu-opioid receptor (MOR), which is the primary target for potent opioid analgesics. LXH-2103 is administered via intravenous injection and is currently undergoing Phase 1 clinical evaluation in China to determine its safety, tolerability, and pharmacokinetic profile in healthy volunteers following single and multiple dosing regimens.

Other names: LXH-2103 injectionLXH2103 injectionLXH 2103 injection

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on LXH-2103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LXH-2103.

Explore the full profile